Kazia in-licenses global rights to SETDB1-targeted epigenetic drug platform

 

 from QIMR Berghofer for $1.39M upfront plus revenue share

• Kazia obtained a first-in-class SETDB1-targeted epigenetic drug development platform that includes lead candidate MSETC from QIMR Berghofer.
• Financial terms comprise approximately $1.39 million upfront plus additional tiered revenue sharing for the in-licensed program.
• Kazia plans to advance the SETDB1 program toward IND-enabling studies alongside its existing PD-L1 degrader program.

https://finviz.com/quote.ashx?t=KZIA&p=d